MCID: BRR014
MIFTS: 64

Barrett Esophagus

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett Esophagus

MalaCards integrated aliases for Barrett Esophagus:

Name: Barrett Esophagus 53 12 49 71 51 41 69
Barrett's Esophagus 12 49 36 28 14
Barrett Esophagus/esophageal Adenocarcinoma 53 13
Barrett's Ulcer of Esophagus 12 69
Barrett Metaplasia 53 71
Barrett Syndrome 72 49
Chronic Peptic Ulcer and Esophagitis Syndrome 49
Barrett's Esophagus with Esophagitis 12
Adenocarcinoma of the Esophagus 55
Adenocarcinoma of Esophagus 69
Esophageal Adenocarcinoma 55
Esophagitis-Peptic Ulcer 49
Columnar-Like Esophagus 49
Barrett's Oesophagus 12
Barretts Syndrome 12
Barrett Ulcer 49
Cle 12
Be 71

Characteristics:

Orphanet epidemiological data:

55
adenocarcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

31
barrett esophagus:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 53 614266
Disease Ontology 12 DOID:9206
ICD9CM 34 530.85
MeSH 41 D001471
NCIt 46 C2891
Orphanet 55 ORPHA99976
UMLS via Orphanet 70 C0279628
ICD10 via Orphanet 33 C15.2 C15.5
KEGG 36 H01901

Summaries for Barrett Esophagus

NIH Rare Diseases : 49 Barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. Although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (GERD). The exact underlying cause of Barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. Treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of GERD. Endoscopic or surgical treatments may be recommended in people with severe cases. Last updated: 7/13/2015

MalaCards based summary : Barrett Esophagus, also known as barrett's esophagus, is related to adenocarcinoma and gastroesophageal reflux, and has symptoms including chest pain, nausea and vomiting and obesity. An important gene associated with Barrett Esophagus is ASCC1 (Activating Signal Cointegrator 1 Complex Subunit 1), and among its related pathways/superpathways are Pathways in cancer and WNT Signaling. The drugs Abstral and Actiq have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and endothelial, and related phenotypes are digestive/alimentary and homeostasis/metabolism

OMIM : 53 Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a columnar and intestinal-type epithelium. This metaplastic change is important because patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett metaplasia is gastroesophageal reflux (GER; 109350). The retrograde movement of acid and bile salts from the stomach into the esophagus in this disease causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes (summary by Wong et al., 2005). (614266)

UniProtKB/Swiss-Prot : 71 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

Wikipedia : 72 Barrett\'s esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the... more...

Related Diseases for Barrett Esophagus

Diseases related to Barrett Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.3 ASCC1 CCND1 CDKN2A CTHRC1 PTGS2 TP53
2 gastroesophageal reflux 31.0 CDX2 PTGS2 TP53
3 esophageal cancer 30.6 CCND1 CDKN2A CDX2 GSTP1 PTGS2 TP53
4 esophagus adenocarcinoma 30.6 CDKN2A CDX2 PTGS2 TP53
5 transitional cell carcinoma 30.4 KRT20 KRT7 PTGS2 TP53
6 gastric cancer 28.9 CCND1 CDKN2A CDX2 GAST GSTP1 KRT20
7 high-grade dysplasia in patients with barrett esophagus 12.1
8 emphysema, congenital lobar 11.8
9 prune belly syndrome 11.6
10 mungan syndrome 11.4
11 leukoencephalopathy with vanishing white matter 11.2
12 visceral myopathy 11.1
13 lupus erythematosus tumidus 10.9
14 lymphoma, hodgkin, classic 10.9
15 leukemia 10.8
16 langerhans cell histiocytosis 10.8
17 diffuse large b-cell lymphoma 10.8
18 follicular lymphoma 10.7
19 hydrocephalus 10.7
20 diarrhea 10.7
21 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
22 acute lymphocytic leukemia 10.7
23 anal gland adenocarcinoma 10.7 KRT7 MUC5AC
24 breast cancer 10.7
25 cap polyposis 10.7 MUC2 MUC5AC
26 adult t-cell leukemia 10.7
27 megakaryocytic leukemia 10.7
28 plasma cell leukemia 10.7
29 anus adenocarcinoma 10.7 KRT7 MUC5AC
30 myeloma, multiple 10.7
31 mucinous intrahepatic cholangiocarcinoma 10.7 CDX2 MUC2 MUC5AC
32 breast papillomatosis 10.7 CCND1 CDKN2A
33 inverted transitional papilloma 10.7 CDKN2A KRT7
34 acth-independent macronodular adrenal hyperplasia 10.7
35 protoplasmic astrocytoma 10.7 PTGS2 TP53
36 squamous cell carcinoma of the oropharynx 10.7 CDKN2A TP53
37 anal canal adenocarcinoma 10.7 CDX2 KRT7 MUC5AC
38 paine syndrome 10.7
39 leukemia, chronic lymphocytic 10.6
40 polyposis, skin pigmentation, alopecia, and fingernail changes 10.6 CDX2 MUC2 MUC5AC
41 congenital toxoplasmosis 10.6
42 hepatitis 10.6
43 bile duct mucoepidermoid carcinoma 10.6 KRT7 MUC2 MUC5AC
44 parkinson disease, late-onset 10.6
45 cystic basal cell carcinoma 10.6 KRT20 KRT7
46 mucinous adenofibroma 10.6 CDX2 KRT7
47 malignant spiradenoma 10.6 KRT7 TP53
48 bladder squamous cell carcinoma 10.6 CDKN2A PTGS2 TP53
49 bladder carcinoma in situ 10.6 CDKN2A KRT7 TP53
50 tonsil squamous cell carcinoma 10.6 CCND1 CDKN2A

Graphical network of the top 20 diseases related to Barrett Esophagus:



Diseases related to Barrett Esophagus

Symptoms & Phenotypes for Barrett Esophagus

Clinical features from OMIM:

614266

Human phenotypes related to Barrett Esophagus:

55 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chest pain 55 31 frequent (33%) Frequent (79-30%) HP:0100749
2 nausea and vomiting 55 31 frequent (33%) Frequent (79-30%) HP:0002017
3 obesity 55 31 hallmark (90%) Very frequent (99-80%) HP:0001513
4 gastroesophageal reflux 55 31 hallmark (90%) Very frequent (99-80%) HP:0002020
5 feeding difficulties in infancy 55 31 hallmark (90%) Very frequent (99-80%) HP:0008872
6 cough 55 31 frequent (33%) Frequent (79-30%) HP:0012735
7 lymphadenopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002716
8 clinodactyly of the 5th toe 55 31 hallmark (90%) Very frequent (99-80%) HP:0001864
9 esophageal carcinoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0011459
10 barrett esophagus 55 31 hallmark (90%) Very frequent (99-80%) HP:0100580

MGI Mouse Phenotypes related to Barrett Esophagus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 CCND1 CDKN2A CDX2 GAST MCM2 MUC2
2 homeostasis/metabolism MP:0005376 9.97 AMACR CCND1 CDKN2A CDX2 CTHRC1 GAST
3 endocrine/exocrine gland MP:0005379 9.96 CCND1 CDKN2A CDX2 GAST GDF7 MCM2
4 immune system MP:0005387 9.7 GAST MCM2 MSR1 MUC2 MUC5AC PTGS2
5 neoplasm MP:0002006 9.23 MUC2 PTGS2 TP53 CCND1 CDKN2A CDX2

Drugs & Therapeutics for Barrett Esophagus

FDA approved drugs:

(show top 50) (show all 194)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abstral 17 FENTANYL (citrate) ProStrakan January 2011
2
Actiq 17 FENTANYL (citrate) Anesta Corporation November 1998
3
Adcetris 17 45 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
4
Afinitor 17 45 EVEROLIMUS Novartis March 2009
5
Akynzeo 17 45 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
6
Aloxi 17 45 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
7
Anexsia 17 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
8
Aredia 17 45 PAMIDRONATE DISODIUM Chiron August 1996
9
Arimidex 17 45 ANASTROZOLE AstraZeneca January 1996
10
Aromasin Tablets 17 45 EXEMESTANE Pharmacia & Upjohn October 21. 1999
11
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005
12
Beleodaq 17 45 BELINOSTAT Spectrum Pharmaceuticals July 2014
13
Blincyto 17 45 BLINATUMOMAB Amgen December 2014
14
Busulfex 17 45 BUSULFAN Orphan Medical February 1999
15
Campostar 17 45 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
16
Cervarix 17 45 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
17
Clolar 17 45 CLOFARABINE Genzyme December, 2004
18
Cometriq 17 45 CABOZANTINIB S-MALATE Exelixis November 2012
19
Degarelix 17 45 degarelix Ferring Pharmaceuticals December of 2008
20
Elitek 17 45 RASBURICASE sanofi-aventis October 2009
21
Ellence 17 45 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
22
Eloxatin 17 45 OXALIPLATIN Sanofi-aventis August 2002
23
Erwinaze 17 45 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
24
Ethyol 17 AMIFOSTINE Alza December 8, 1995
25
Eulexin 17 FLUTAMIDE Schering-Plough June 1996
26
Evista 17 45 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
27
Farydak 17 45 PANOBINOSTAT LACTATE Novartis February 2015
28
Faslodex 17 45 FULVESTRANT AstraZeneca April 2002
29
Folotyn 17 45 PRALATREXATE Allos Therapeutics September 2009
30
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
31
Gardasil 17 45 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
32
Gemzar 17 45 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
33
Gilotrif 17 45 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
34
Hycamtin 17 45 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
35
Ibrance 17 45 PALBOCICLIB Pfizer February 2015
36
Iclusig 17 45 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
37
Imbruvica 17 45 IBRUTINIB Pharmacyclics November of 2013/February 2014
38
Inlyta 17 45 AXITINIB Pfizer January 2012
39
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
40
Iressa 17 45 GEFITINIB AstraZeneca May 2003
41
Istodax 17 45 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
42
Ixempra 17 45 IXABEPILONE Bristol-Myers Squibb October 2007
43
Jevtana 17 45 CABAZITAXEL sanofi aventis June 2010
44
Kadcyla 17 45 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
45
Kadian 17 MORPHINE SULFATE Purepac Pharmaceutical July 1996
46
Keytruda 17 45 PEMBROLIZUMAB Merck September 2014
47
Kyprolis 17 45 CARFILZOMIB Onyx Pharmaceuticals July 2012
48
Lazanda 17 FENTANYL CITRATE Archimedes June 2011
49
Lenvima 17 45 LENVATINIB MESYLATE Eisai February 2015
50
Leukine 17 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996

Drugs for Barrett Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 9579578 4594
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1 73590-58-6 4594
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
5
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
7
Dinoprostone Approved Phase 4 363-24-6 5280360
8
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
9
Phenylephrine Approved Phase 4 59-42-7 6041
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13 Liver Extracts Phase 4
14 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Anesthetics Phase 4,Early Phase 1
19 Hormones Phase 4,Phase 2,Early Phase 1
20 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Analgesics Phase 4,Phase 3,Phase 2
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
25 Antipyretics Phase 4,Phase 3,Phase 2
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2
27 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2
28 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
29 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
31 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
32 Neuroprotective Agents Phase 4,Phase 1
33 Antiemetics Phase 4
34 Antineoplastic Agents, Hormonal Phase 4,Early Phase 1
35 Autonomic Agents Phase 4
36 glucocorticoids Phase 4
37 Hormone Antagonists Phase 4,Phase 2,Early Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Early Phase 1
39 Methylprednisolone acetate Phase 4
40 Methylprednisolone Hemisuccinate Phase 4
41 Prednisolone acetate Phase 4
42 Prednisolone hemisuccinate Phase 4
43 Prednisolone phosphate Phase 4
44 Omega 3 Fatty Acid Nutraceutical Phase 4
45
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
46
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
47
Pantoprazole Approved Phase 3 102625-70-7 4679
48
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
49
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
50
acetic acid Approved, Nutraceutical Phase 2, Phase 3 64-19-7 176

Interventional clinical trials:

(show top 50) (show all 246)

# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4 Esomeprazole;Lansoprazole
3 Barrett's Esophagus - 315 - 3 Way Cross-Over Completed NCT00637559 Phase 4 Esomeprazole Magnesium
4 Barrett's Esophagus - 315 - 3 Way Cross Over Completed NCT00637988 Phase 4 Esomeprazole;Aspirin;Rofecoxib
5 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
6 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
7 Radiofrequency Ablation for the Treatment of Gastric Dysplasia Completed NCT01523912 Phase 4
8 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
9 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids Recruiting NCT01733147 Phase 4 Omega-3 free fatty acids;Placebo
10 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
11 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4 Prednisolone
12 Cryo Balloon for Residual Barrett's Esophagus Enrolling by invitation NCT02230410 Phase 4
13 Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Terminated NCT00526786 Phase 4
14 A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies Terminated NCT01030263 Phase 4
15 Reduction in Symptomatic Esophageal Stricture Formation Terminated NCT02039115 Phase 4 prednisone;placebo
16 Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study Unknown status NCT01566474 Phase 3 Omeprazole;Melatonin
17 Biomarkers in Phototherapy of Barrett's Esophagus Completed NCT00587600 Phase 2, Phase 3
18 Barrett's Esophagus & Gastroesophageal Reflux Disease Completed NCT00513331 Phase 2, Phase 3
19 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
20 "Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance Recruiting NCT02614703 Phase 2, Phase 3 Chromoendoscopy using Acetic Acid 2.5%
21 An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric Recruiting NCT03285906 Phase 2, Phase 3 Apatinib
22 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
23 Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor Terminated NCT00161200 Phase 3 Ranitidine & Pantoprazole
24 Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE) Withdrawn NCT01209013 Phase 3
25 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
26 Screening for Barrett's Esophagus in Otolaryngology Patients Unknown status NCT00695227 Phase 2 Proton Pump Inhibitor
27 Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT01447927 Phase 2 metformin hydrochloride
28 Novel Method of Surveillance in Barrett's Esophagus Completed NCT00955019 Phase 2
29 Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT00474903 Phase 2 acetylsalicylic acid;esomeprazole magnesium
30 Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium Completed NCT02249975 Phase 1, Phase 2
31 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
32 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Completed NCT01097304 Phase 2 Ursodiol
33 Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00005878 Phase 2 celecoxib
34 Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00003076 Phase 2 eflornithine
35 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
36 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
37 Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed NCT00002935 Phase 2 porfimer sodium
38 Radiofrequency Ablation for Gastric Metaplasia and Dysplasia Completed NCT01614418 Phase 1, Phase 2
39 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus Recruiting NCT03193216 Phase 2 Alginates
40 Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation Recruiting NCT02521285 Phase 2 Aspirin
41 Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Recruiting NCT02018367 Phase 2 Proflavine, high resolution imaging
42 Autologous Cell Sheets Transplantation After ESD in the Esophagus Recruiting NCT02455648 Phase 2
43 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
44 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Active, not recruiting NCT01298999 Phase 2 YF476;Placebo
45 Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia Active, not recruiting NCT01360541 Phase 2
46 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2 YF476;YF476 placebo
47 Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation Terminated NCT02162758 Phase 2 Dexlansoprazole;Dexlansoprazole Placebo
48 Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer Terminated NCT00321958 Phase 2
49 Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light Withdrawn NCT01256203 Phase 2 Solar Protection Formula SPF® 60
50 The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus Unknown status NCT01905202 Phase 1 Secretrol

Search NIH Clinical Center for Barrett Esophagus

Cochrane evidence based reviews: barrett esophagus

Genetic Tests for Barrett Esophagus

Genetic tests related to Barrett Esophagus:

# Genetic test Affiliating Genes
1 Barrett's Esophagus 28 ASCC1 CTHRC1 MSR1

Anatomical Context for Barrett Esophagus

MalaCards organs/tissues related to Barrett Esophagus:

38
Lung, Breast, Endothelial, Skin, Testes, Prostate, Heart

Publications for Barrett Esophagus

Articles related to Barrett Esophagus:

(show top 50) (show all 78)
# Title Authors Year
1
Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient's Entire Set of Biopsies. ( 29135518 )
2018
2
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
3
Efficacy, Durability, and Safety of Complete Endoscopic Mucosal Resection of Barrett Esophagus: A Systematic Review and Meta-Analysis. ( 28134635 )
2018
4
Definition of Barrett Esophagus in the United States: Support for Retention of a Requirement for Goblet Cells. ( 29016405 )
2018
5
Treating Barrett esophagus with radiofrequency ablation. ( 29280837 )
2018
6
Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial. ( 29369237 )
2018
7
Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer. ( 29384778 )
2018
8
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
9
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. ( 28422774 )
2017
10
Hepatocyte Antigen Expression in Barrett Esophagus and Associated Neoplasia. ( 28187035 )
2017
11
The Use of Ancillary Stains in the Diagnosis of Barrett Esophagus and Barrett Esophagus-associated Dysplasia: Recommendations From the Rodger C. Haggitt Gastrointestinal Pathology Society. ( 28248814 )
2017
12
Current Management of Low-Grade Dysplasia in Barrett Esophagus. ( 28546793 )
2017
13
Barrett Esophagus ( 28613697 )
2017
14
Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma. ( 28501084 )
2017
15
Human papillomavirus does not play a role in the Barrett esophagus: a French cohort. ( 28881904 )
2017
16
Early Barrett esophagus-related neoplasia in segments 1a88cm or longer is always associated with intestinal metaplasia. ( 28548120 )
2017
17
Acetic Acid Chromoendoscopy in the Setting of Neoplastic Barrett Esophagus. ( 28867985 )
2017
18
Hybrid Argon Plasma Coagulation in Patients With Barrett Esophagus. ( 29230137 )
2017
19
Current Endoscopic Approaches for the Treatment of Barrett Esophagus. ( 27941583 )
2017
20
Prevalence of Barrett Esophagus in Adolescents and Young Adults With Esophageal Atresia. ( 27163954 )
2016
21
Volumetric Laser Endomicroscopy in Patients With Barrett Esophagus. ( 28035200 )
2016
22
RING finger proteins are involved in the progression of barrett esophagus to esophageal adenocarcinoma: a preliminary study. ( 25228972 )
2014
23
Barrett esophagus and risk of esophageal cancer: a clinical review. ( 23942681 )
2013
24
Barrett esophagus and esophagojejunal anastomotic stenosis as complications of esophagogastric disconnection in children with esophageal atresia. ( 23535759 )
2013
25
Current readings: Endoesophageal management of early esophageal cancer and dysplastic barrett esophagus: a review of recent and influential studies. ( 24216531 )
2013
26
Advanced esophageal cancer in patients who underwent radiofrequency ablation for barrett esophagus with high-grade dysplasia. ( 23571789 )
2013
27
Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. ( 23108119 )
2013
28
Metastatic melanoma in an esophagus demonstrating Barrett esophagus with high grade dysplasia. ( 24220097 )
2013
29
Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? ( 22261707 )
2012
30
Inverse association of esophageal eosinophilia and Barrett esophagus. ( 22751337 )
2012
31
Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. ( 22603795 )
2012
32
Expression of androgen receptors in Barrett esophagus. ( 22327304 )
2012
33
Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. ( 22344232 )
2012
34
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. ( 22355271 )
2012
35
Patients with partial gastrectomy and Barrett esophagus are in higher risk to develop esophageal adenocarcinoma than those with Barretts without gastrectomy. ( 22580662 )
2012
36
Immunohistochemical staining for smoothelin in the duplicated versus the true muscularis mucosae of Barrett esophagus. ( 21164287 )
2011
37
Barrett esophagus after surgical treatment for achalasia. ( 21857487 )
2011
38
Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma. ( 21617543 )
2011
39
Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. ( 21791690 )
2011
40
Combined tubular adenocarcinoma and hepatoid adenocarcinoma arising in Barrett esophagus. ( 20952273 )
2011
41
Esophagitis and Barrett esophagus: unifying the definitions and diagnostic approaches, with special reference to esophageal atresia. ( 21499040 )
2011
42
Foveolar type dysplasia in Barrett esophagus. ( 20228780 )
2010
43
[Expression of c-myb in reflux esophagitis, Barrett esophagus and esophageal adenocarcinoma]. ( 21177182 )
2010
44
Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues. ( 20543560 )
2010
45
Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy. ( 19475154 )
2009
46
Esophageal adenocarcinoma arising in Barrett esophagus. ( 18703277 )
2009
47
Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. ( 18510604 )
2008
48
p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. ( 18665038 )
2008
49
Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. ( 18334729 )
2008
50
CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. ( 18343784 )
2008

Variations for Barrett Esophagus

ClinVar genetic disease variations for Barrett Esophagus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh37 Chromosome 8, 16021631: 16021631
2 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh37 Chromosome 8, 104384015: 104384015
3 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Pathogenic rs146370051 GRCh37 Chromosome 10, 73892817: 73892817

Copy number variations for Barrett Esophagus from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma

Expression for Barrett Esophagus

Search GEO for disease gene expression data for Barrett Esophagus.

Pathways for Barrett Esophagus

GO Terms for Barrett Esophagus

Biological processes related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.58 CCND1 CDKN2A MCM2
2 response to estradiol GO:0032355 9.54 CCND1 GSTP1 PTGS2
3 replicative senescence GO:0090399 9.32 CDKN2A TP53
4 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC2 MUC6
5 mitotic G1 DNA damage checkpoint GO:0031571 9.16 CCND1 TP53
6 O-glycan processing GO:0016266 9.13 MUC2 MUC5AC MUC6
7 response to organonitrogen compound GO:0010243 8.8 CCND1 PTGS2 TP53

Sources for Barrett Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....